Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Sebastian

Showing results (141-150 of 183) with videos related to

Pageof 19
Sort By:
Frontiers in Oncology|October 9, 2023
Survival benefit with checkpoint inhibitors versus chemotherapy is modified by brain metastases in patients with recurrent small cell lung cancerFriederike C Althoff, Lisa V Schäfer, Fabian Acker, et al.
Critical Care Explorations|November 23, 2020
Camostat Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First ObservationHeike Hofmann-Winkler, Onnen Moerer, Sabine Alt-Epping, et al.
International Journal of Cancer|February 8, 2024
Patient-reported outcomes in advanced NSCLC before and during the COVID-19 pandemic: Real-world data from the German prospective CRISP Registry (AIO-TRK-0315)Martin Sebastian, Wilfried E E Eberhardt, Eyck von der Heyde, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 19, 2024
Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3Jhanelle E Gray, Aleksandra Markovets, Thanyanan Reungwetwattana, et al.
Therapeutic Advances in Medical Oncology|June 9, 2021
A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancerMartin Metzenmacher, Hans-Georg Kopp, Frank Griesinger, et al.
The New England Journal of Medicine|December 14, 2016
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung CancerTony S Mok, Yi-Long Wu, Myung-Ju Ahn, et al.
JHEP Reports : Innovation in Hepatology|January 19, 2026
Blood-based Vienna 3P/5P risk models accurately predict first hepatic decompensation in compensated advanced chronic liver diseaseGeorg Kramer, Benedikt Simbrunner, Mathias Jachs, et al.
Lung Cancer (Amsterdam, Netherlands)|October 9, 2024
A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancerDavid Planchard, Jürgen Wolf, Benjamin Solomon, et al.
The European Respiratory Journal|September 30, 2022
Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registryMartin Metzenmacher, Frank Griesinger, Horst-Dieter Hummel, et al.
JHEP Reports : Innovation in Hepatology|February 25, 2026
Development and patterns of acute-on-chronic liver failure in patients with cirrhosis and acute kidney injurySusan Fischer, Martin Sebastian McCoy, Marta Fiocco, et al.
Pageof 19

Showing results (141-150 of 183) with videos related to

Sort By:
Pageof 19
Frontiers in Oncology|October 9, 2023
Survival benefit with checkpoint inhibitors versus chemotherapy is modified by brain metastases in patients with recurrent small cell lung cancerFriederike C Althoff, Lisa V Schäfer, Fabian Acker, et al.
Critical Care Explorations|November 23, 2020
Camostat Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First ObservationHeike Hofmann-Winkler, Onnen Moerer, Sabine Alt-Epping, et al.
International Journal of Cancer|February 8, 2024
Patient-reported outcomes in advanced NSCLC before and during the COVID-19 pandemic: Real-world data from the German prospective CRISP Registry (AIO-TRK-0315)Martin Sebastian, Wilfried E E Eberhardt, Eyck von der Heyde, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 19, 2024
Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3Jhanelle E Gray, Aleksandra Markovets, Thanyanan Reungwetwattana, et al.
Therapeutic Advances in Medical Oncology|June 9, 2021
A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancerMartin Metzenmacher, Hans-Georg Kopp, Frank Griesinger, et al.
The New England Journal of Medicine|December 14, 2016
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung CancerTony S Mok, Yi-Long Wu, Myung-Ju Ahn, et al.
JHEP Reports : Innovation in Hepatology|January 19, 2026
Blood-based Vienna 3P/5P risk models accurately predict first hepatic decompensation in compensated advanced chronic liver diseaseGeorg Kramer, Benedikt Simbrunner, Mathias Jachs, et al.
Lung Cancer (Amsterdam, Netherlands)|October 9, 2024
A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancerDavid Planchard, Jürgen Wolf, Benjamin Solomon, et al.
The European Respiratory Journal|September 30, 2022
Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registryMartin Metzenmacher, Frank Griesinger, Horst-Dieter Hummel, et al.
JHEP Reports : Innovation in Hepatology|February 25, 2026
Development and patterns of acute-on-chronic liver failure in patients with cirrhosis and acute kidney injurySusan Fischer, Martin Sebastian McCoy, Marta Fiocco, et al.
Pageof 19